1. FRI0137 Efficacy, safety and immunogenicity from week 30 to week 54 in a randomised, double-blind phase iii study comparing a proposed infliximab biosimilar (PF-06438179/GP1111) with reference infliximab. (12th June 2018) Authors: Alten, R.; Tseluyko, V.; Hala, T.; Mehmedagic, S.; Pileckyte, M.; Dokoupilová, E.; Jovic, D.; Rehman, M.; Zhang, M.; Sewell, L.; Hackley, S.; Salts, S.; Cronenberger, C.; Schumacher, K.; von Richter, O.; Batko, B. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 612 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗